Lumena raises $23M to advance liver-disease drug

05/9/2013 | American City Business Journals

A Series A funding round has brought in $23 million to Lumena Pharmaceuticals, a California-based biotech firm founded by Pappas Ventures. Proceeds will go toward the development of the company's lead drug candidate for cholestatic liver disease. Lumena plans to conduct midstage trials of the drug in adults with primary biliary cirrhosis and in children with alagille syndrome and progressive familial intrahepatic cholestasis.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX